IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED
IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED is a Private Limited Company, incorporated under the Companies Act as a Company limited by Shares. It is classified as Non-govt company and is registered at RoC-Mumbai.
There are 2 promoter(s) of the company viz.Rahul Purwar, Shalini Rahul Purwar .
IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED Annual General Meeting (AGM) was last held on as per records from the Ministry of Corporate Affairs (MCA).
Financial Details & Insights
The authorized share capital of the company is Rs.5,00,000 and its paid up capital is Rs.1,00,000. Its balance sheet was last filed on None. IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED Corporate Identification Number (CIN) is U74999MH2018PTC315497 and its registration number is 315497.
Contact Details & Insights
You can contact them by emailing at purwarrahul@utb.ac.in. The companies registered address is CM-05, SINE Office, 3rd Floor CSRE Building, IIT Bombay, Powai MUMBAI Mumbai City MH 400076 IN.
Other Details & Information
IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED's status is Active as per the records. The company is Unlisted.
CIN | U74999MH2018PTC315497 |
Company Name | IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED |
ROC Code | RoC-Mumbai |
Registration Number | 315497 |
Company Category | Company limited by Shares |
Company SubCategory | Non-govt company |
Class of Company | Private |
Authorised Capital(Rs) | 5,00,000 |
Paid up Capital(Rs) | 1,00,000 |
Number of Members (Applicable in case of company without Share Capital) | 0 |
Date of Incorporation | 08-10-2018 |
Registered Address | CM-05, SINE Office, 3rd Floor CSRE Building, IIT Bombay, Powai MUMBAI Mumbai City MH 400076 IN |
Email Id | purwarrahul@utb.ac.in |
Whether Listed or not | Unlisted |
Date of Last AGM | |
Date of Balance Sheet | |
Company Status (for efiling) | Active |
Last Updated On | 20-12-2018 |
Directors/Signatory Details
DIN/PAN | Name | Begin Date |
---|---|---|
08251942 | Rahul Purwar | 08-10-2018 |
08251943 | Shalini Rahul Purwar | 08-10-2018 |